| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8523330 | Antiviral Research | 2018 | 6 Pages |
Abstract
Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Hakan Leblebicioglu, Joop E. Arends, Resat Ozaras, Giampaolo Corti, Lurdes Santos, Christoph Boesecke, Andrew Ustianowski, Ann-Sofi Duberg, Simona Ruta, Nermin N. Salkic, Petr Husa, Ivana Lazarevic, Juan A. Pineda, Natalia Yurievna Pshenichnaya,